Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Switch Treatment in Schizophrenia Patients on Risperidone
NCT00232687Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, open-label trial of aripiprazole in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Proportion of patients who discontinue because of Adverse Events up to 22 months. Started Jun 2005; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00232687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232687.